<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens </plain></SENT>
<SENT sid="3" pm="."><plain>In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>